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The Journal of Immunology
Visualizing the Role of Cbl-b in Control of Islet-Reactive CD4
T Cells and Susceptibility to Type 1 Diabetes
Gerard F. Hoyne,* Eleanor Flening,* Mehmet Yabas,* Charis Teh,* John A. Altin,*
Katrina Randall,* Christine B. F. Thien,† Wallace Y. Langdon,† and Christopher C. Goodnow*
TheE3ubiquitin ligaseCbl-b regulatesTcell activation thresholds andhasbeenassociatedwithprotectingagainst type1diabetes, but
its invivo role in theprocessof self-tolerancehasnotbeenexaminedat the level of potentially autoaggressiveCD4+Tcells. In this study,
we visualize the consequences of Cbl-b deficiency on self-tolerance to lysozyme Ag expressed in transgenic mice under control of the
insulin promoter (insHEL). By tracing the fate of pancreatic islet-reactive CD4+ T cells in prediabetic 3A9-TCR3 insHEL double-
transgenic mice, we find that Cbl-b deficiency contrasts with AIRE or IL-2 deficiency, because it does not affect thymic negative
selection of islet-reactive CD4+ cells or the numbers of islet-specific CD4+ or CD4+Foxp3+ T cells in the periphery, although it
decreased differentiation of inducible regulatory T cells from TGF-b–treated 3A9-TCR cells in vitro. When removed from regula-
tory T cells and placed in culture, Cblb-deficient islet-reactive CD4+ cells reveal a capacity to proliferate to HEL Ag that is repressed
in wild-type cells. This latent failure of T cell anergy is, nevertheless, controlled in vivo in prediabetic mice so that islet-reactive CD4+
cells in the spleen and the pancreatic lymph node of Cblb-deficient mice show no evidence of increased activation or proliferation in
situ. Cblb deficiency subsequently precipitated diabetes in most TCR:insHEL animals by 15 wk of age. These results reveal a role for
peripheral T cell anergy in organ-specific self-tolerance and illuminate the interplay between Cblb-dependent anergy and other
mechanisms for preventing organ-specific autoimmunity. The Journal of Immunology, 2011, 186: 000–000.
O
rgan-specific autoimmune diseases, such as type 1 di-
abetes, appear to result from inherited defects in different
cellular checkpoints for acquiring self-tolerance within
the T cell repertoire. Rare monogenic syndromes of organ-specific
autoimmunity in humans—coupled with cellular analysis of mice
bearing corresponding gene defects—have illuminated critical
roles for the AIRE transcription factor in thymic deletion of
organ-specific T cells (1–5) and for Foxp3, IL-2, and IL-2R
a-chain in thymic formation of regulatory T cells (Tregs) (6–
14). Analyses of polygenic susceptibility to autoimmunity also
implicates defects in specific T cell tolerance checkpoints, notably
subtle genetic variants of IL2RA and IL-2 associated with type 1
diabetes in humans and NOD mice, respectively, and polygenic
defects in TCR signaling for thymic deletion in NOD mice (3, 15–
19). Spontaneous type 1 diabetes in the Komeda diabetes-prone
(KDP) rat results from cooperation between a specific MHC
haplotype—probably MHC class II—and a truncating mutation
in the gene encoding Cbl-b (20–22). However, it is not known
whether Cbl-b deficiency disrupts thymic deletion of MHC class
II-restricted diabetogenic CD4+ cells, formation of islet-specific
Foxp3 T cells, or other peripheral self-tolerance checkpoints. Cbl-
b has been linked to T cell anergy induction by the pharmaco-
logical agent ionomycin in vitro or upon artificial exposure to high
concentrations of foreign peptides in vivo (23), but there is in fact
little direct evidence for T cell anergy as a physiological mecha-
nism for organ-specific self-tolerance and no information on how
a defect in T cell anergy might be manifest in diabetogenic T cells.
Cbl-b and its close paralogue, c-Cbl, function as E3 ubiquitin
ligases that regulate cell surface expression of activated receptors
with receptor tyrosine kinase activity (e.g., the epidermal growth
factor receptor) through endocytosis and targeting them for
ubiquitin-mediated degradation (24, 25). Thymocytes predomi-
nantly express c-Cbl, whereas Cbl-b is more abundant in mature
T cells (25, 26). C-Cbl is required for TCR sequestration and
downregulation in thymocytes, whereas the two proteins appear to
function redundantly for promoting TCR downregulation in pe-
ripheral T cells (23, 27, 28). Peripheral T cells from Cbl-b–de-
ficient mice express relatively normal TCR levels on their surface
but have a lower Ag concentration threshold for acute activation
in vitro and can be activated to proliferate and synthesize cyto-
kines in the absence of the normal requirement for CD28 co-
stimulation (27, 29–33). Cbl-b–deficient T cells exhibit normal
TCR-induced activation but show enhanced formation of three key
TCR signaling events that normally depend on CD28 costimula-
tion: NF-kB activation through the PI3K/Akt/protein kinase C-u–
Carma-1 pathway (34), FOXO-3a inactivation through the PI3K–
Akt pathway (35, 36), and stable clustering of TCR with lipid rafts
and signaling components in the T cell synapse (37). In response
to viral infection, Cbl-b–deficient T cells undergo clonal expan-
sion followed by a decline in numbers that is comparable to wild-
type T cells, although during chronic infection, the deficient
T cells resist the shutdown of IFN-g secretion that occurs during
“exhaustion” of wild-type CD8 cells (32). These data firmly
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establish a unique role for Cbl-b in regulating naive T cell acti-
vation in response to foreign Ags.
The role of T cell anergy as a physiological self-tolerance
mechanism is unclear. In tissue culture, T cell clones that receive
a sustained TCR calcium signal in the absence of a CD28 costim-
ulus are rendered unable to synthesize IL-2 and proliferate upon
restimulation (38, 39). Because Cbl-b–deficient T cells are able to
proliferate and make IL-2 without CD28 costimulation (27, 29),
and Cbl-b together with other ubiquitin ligases is induced by
chronic calcium–NFAT signaling mediated by the TCR or by the
pharmacological agent ionomycin (37, 40), it has been suggested
that Cbl-b is part of a program for physiological self-tolerance by
T cell anergy. However, experimental studies of T cell anergy
in vivo rely on acutely triggering naive T cells with high concen-
trations of foreign Ag in the absence of adjuvant (23). This does
not trigger the outcome observed in T cells in culture, but instead,
the T cells are triggered into several rounds of cell division in vivo
followed by death of many of the T cell progeny. The residual cells
are refractory to TCR-induced proliferation when placed in tissue
culture, and this refractory state is diminished when the T cells lack
Cbl-b (23). Although this high-zone desensitization regimen mir-
rors T cell exhaustion during chronic viral infection (32), it is not
clear that the same process occurs in concert with clonal deletion
and Treg formation during self-tolerance.
In this study, we analyze the effect of Cbl-b deficiency on the
processes of self-tolerance occurring in CD4+ T cells that express
a high-affinity transgenic TCR for a neo self-Ag (hen egg lyso-
zyme; insHEL) that is expressed as an abundant membrane protein
on pancreatic b cells (41). In these animals, most islet-reactive
CD4+ T cells are deleted in the thymus through an Aire-dependent
mechanism of insHEL expression on thymic medullary epithelial
cells (3, 4). A subset of the islet-reactive CD4 cells escape deletion
and are induced in the thymus to become Foxp3+CD25+ cells by
a process that depends on IL-2 (12), whereas others escape both
these fates but appear quiescent in the periphery for reasons that
are unexplored. We find that Cbl-b deficiency leaves intact both
Aire-dependent thymic deletion and IL-2–dependent Treg for-
mation of islet-reactive CD4 cells and selectively cripples an in-
trinsic silencing of the proliferative response by islet-reactive cells
that escape these other checkpoints. Cbl-b deficiency lead to a
defect in islet-specific CD4 T cell anergy, as well as a defect in
TGF-b–induced Foxp3 expression and suppressive activity of




3A9 TCR transgenic and ILK-3 insHEL transgenic mice produced in
C57BL/6J mice were backcrossed more than 7 generations to B10.Br/
SgSnJ (B10k JAX). Cblb2/2 mice (29), were backcrossed to C57BL/6
for 10 generations, and then backcrossed 3 generations to B10.Br 3A9
TCR:insHEL transgenic mice. Genotyping for the Cblb mutation was
performed by multiplex PCR genotyping. Genomic DNA was prepared
and amplified using a unique allele-specific forward primer that could
distinguish the wild-type and mutant Cblb gene, whereas the reverse
primer was common to both genotypes. All mice were bred and pur-
chased from the Australian Phenomics Facility, Australian National
University. All mice were housed in specific pathogen-free conditions
(Canberra, Australian Capital Territory, Australia), and all animal pro-
cedures were approved by the Australian National University Animal
Ethics and Experimentation Committee.
Abs and flow cytometry
Cell suspensions of spleen or thymus were prepared by sieving and gentle
pipetting. For surface staining, cells were added at 23 106 cells/well andwere
maintained in the dark at 4˚C throughout. Cells werewashed twice in ice-cold
FACS buffer (2% FCS and 0.02%NaN3 in PBS) and then incubatedwith each
Ab and conjugate layer for 30 min and washed thoroughly with FACS buffer
between each layer. The following Abs were used (all from BD Biosciences,
except where otherwise indicated): CD3ε-FITC, CD4-PerCP, CD4-allophy-
cocyanin, CD4-FITC, CD5-PE, CD8-FITC, CD8-PE (Caltag Laboratories),
CD8-PerCP,CD45.2-FITC,CD45.2-allophycocyanin,CD45.1-FITC,CD45.1-
PE, L-selectin (CD62L)-biotin, B220-PerCP, B220-allophycocyanin, B220-
PE, B220-biotin, CD19-PE, CD19-PE, CD25-allophycocyanin, CD69-FITC,
CD69-biotin, andCD90-PE (BDPharmingen). SecondaryAbs and streptavidin
(SA) conjugates were as follows: rat-anti–mouse IgG1-allophycocyanin, rabbit
anti–rat-IgG-biotin (DakoCytomation), SA-PE, SA-allophycocyanin, and SA-
Cychrome.Datawere acquired on a FACSCalibur flow cytometer and analyzed
using FlowJo software. Cells were sorted on a FACSVantage (BDBiosciences).
The rat-anti–mouse 1G12 mAb was a gift from E. Unanue and D. Peterson
(Washington University School of Medicine, St. Louis, MO).
CFSE labeling
Cells were suspended at 5 3 107/ml in warm RPMI 1640 medium and
incubated for 10 min at 37˚C with 5 mM CFSE (Molecular Probes). La-
beling was quenched with three washes of ice-cold RPMI 1640 medium/
10% FCS. At the end of the culture period, cells were collected, washed,
and stained with anti–CD4-allophycocyanin, anti–CD8-PE, 1G12/rat-anti–
mouse IgG1 Abs (all from BD Pharmingen), and 7-aminoactinomycin D
(Molecular Probes). Data were collected on a FACSCalibur (BD Bio-
sciences) using CellQuest Pro and FlowJo (Tree Star) software analysis
packages.
Diabetes incidence study
Diabetes incidence was measured using urine glucose testing with Diastix
at weekly intervals or when a cage was wet. To be recorded as diabetic
mice had to be diastix 4+ on at least two readings tested 1 wk apart. Nondia-
betic mice were culled at 24 wk.
T cell culture
Single-cell suspensions of spleen cells from TCR or TCR:insHel mice were
prepared by passing a whole spleen through a 70-mm nylon cell strainer in 5
ml R10 media (RPMI 1640 medium, 10% FCS, 3% penicillin/streptomycin/
L-glutamine, 0.1 mm/ml 2-ME, 1% MEM, 1% HEPES, and 1% sodium
pyruvate), and the cells were centrifuged (7 min, 1500 rpm, 4˚C) and re-
suspended in 5 ml R10 culture medium. The cell density was adjusted to
2 3 106 cells/ml, and 200 ml cells was plated on 96-well flat-bottom plates
(Costar). HEL protein Ag was added at the indicated concentrations, and
the cells were incubated for 72 h at 37˚C. Cells were counted by preparing
a 1:20 dilution of cells in trypan blue to stain dead cells. The cells were
pulsed with [3H]thymdine for 6 h before the cells were harvested onto glass
fiber filter papers and assayed using liquid scintillation chromatography
(Topcount; Packard). To examine intracellular cytokine production, splenic
CD4+ T cells were cultured in vitro in the presence of PMA plus ionomycin
for 6 h in total, but over the last 2 h of culture, GolgiStop was added. Cells
were stained with cell surface Abs and permeabilized and fixed prior to the
addition of anti–IL-4, anti–IFN-g, and anti–IL-17 secondary Abs. Cells
were analyzed by flow cytometry.
iTreg development in vitro
Ninety-six-well microtiter plates (Nunc Maxisorp; eBioscience, San Diego,
CA) were coated with 5 mg/ml anti-CD3 and 2 mg/ml anti-CD28. Spleen
cells were obtained from wild-type, 3A9 wild-type, and 3A9 Cblb2/2 mice
and were purified by FACS sorting to isolate CD4+CD62L+,CD252,
CD442 cells from wild-type, 3A9 wild-type, and 3A9 Cblb2/2. The cells
were cultured in vitro in the presence of 0.5 and 0.1 ng/ml recombinant
human TGF-b for 3 d at 37˚C, and 5 ng/ml recombinant human IL-2 was
added for an additional 2 d. At the end of the culture period, the cells were
stained and analyzed by flow cytometry to determine the frequency of
CD4+CD25+Foxp3+ cells in the culture.
Suppression assay with iTregs in vitro
Naive responder T cells (CD4+CD62L+,CD252,CD442) were FACS sorted
from the spleen of wild-type mice. The cells were washed and labeled with
5 mM CFSE for 10 min at 37˚C in PBS/0.1% BSA. T-depleted splenocytes
from wild-type mice were used as APCs and were obtained by FACS
sorting CD32CD82CD42 cells. Ninety-six-well microtiter plates (Nunc
Maxisorp; eBioscience) were coated with 5 mg/ml anti-CD3, and 105
CFSE-labeled naive T cells plus 105 iTregs plus 5 3 105 T-depleted
splenocytes were cultured in a 96-well plate. The cells were cultured at
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37 C for 3 d and then harvested, stained, and analyzed by flow cytometry
for CFSE dilution.
Anti-Hel IgG ELISAs
Serum levels of anti-HEL Abs were detected using the ELISA system.
Ninety-six-well microtiter plates (Nunc Maxisorp; eBioscience) were
coated with 100 ml of 100 mg/ml HEL in carbonate buffer overnight at 4˚C.
Plates were washed twice with PBS 2% FCS and blocked with 100 ml PBS
and 50% FCS for 2 h at room temperature. Plates were washed twice with
PBS 0.5% Tween 20, and serum samples were then added in a 1:50 di-
lution. Samples were incubated for 45 min at room temperature. Plates
were washed three times with PBS 0.5% Tween 20, and alkaline phos-
phatase-conjugated secondary Abs were added (anti-mouse IgM, 1/500;
anti-mouse IgG1, 1/1000; anti-mouse IgG, 1/1000; BD Pharmingen) for 45
min at room temperature. After washing twice with PBS 0.5% Tween 20,
once with autoclaved H2O and once with ELISA substrate buffer, plates
were developed using Sigma Phosphatase substrate at 2 mg/ml in ELISA
substrate buffer for 30 min. Plates were read using the Molecular Devices
ThermoMax microplate reader (Sunnyvale, CA) plate reader and Softmax
(San Diego, CA) software.
Bone marrow chimeras
Bone marrow chimeras were made by injecting 2 3 106 T cell-depleted bone
marrowcells fromCblb+/+orCblb2/23A9TCR transgenic donors i.v. intoB10.
BR or B10.BR:insHel transgenic mice that had first been conditioned with two
doses of 5 Gy gamma irradiation (Cs source; CSIRO, Canberra, Australian
Capital Territory, Australia) given 3 h apart. The recipient animals were given
water containing antibiotics for the first 3 wk, and mice were analyzed between
8 and 12 wk postinjection, at which time none were glucosuric.
Statistical analysis
Analysis was performed Student t test. The analysis of anti-Hel IgG levels
was determined using ANOVA. The diabetes incidence was analyzed by
log-rank test.
Results
Cblb deficiency precipitates diabetes and anti-islet
autoantibodies in TCR:insHEL transgenic mice
To study the role of Cbl-b in regulation of self-tolerance to an islet-
specific Ag Cblb2/2, mice were bred with 3A9 TCR 3 insHel
double-transgenic mice. The 3A9 TCR is I-Ak restricted, directs
T cell development toward the CD4+ lineage, and recognizes the
immunodominant 46–61 peptide of HEL bound to I-Ak (41, 42).
The transgene carried by insHEL mice encodes a membrane-
bound form of lysozyme under transcriptional control of the rat
insulin promoter. The insHEL gene mirrors the pattern of pro-
insulin gene expression, with high expression in all pancreatic
islet b cells (41) and lower expression in medullary thymic epi-
thelial cells (3, 4). As a result of high numbers of islet-reactive
CD4 T cells produced in the thymus, B10.BR TCR:insHEL mice
develop insulitis, but none develop anti-HEL IgG autoantibodies
(Fig. 1B) and ,25% develop type 1 diabetes (Fig. 1A). The low
incidence of diabetes in the B10.Br double transgenic mice
reflects Aire-dependent thymic deletion (3, 4) and IL-2–dependent
thymic formation of islet-specific CD4+Foxp3+ cells (12), because
.90% of B10.BR TCR:insHEL mice with Aire or Il2 mutations
lacking these mechanisms develop diabetes.
A similar increase in progression to diabetes occurred upon
breeding the Cblb mutation into B10.BR TCR:insHel mice, with
FIGURE 1. Loss of Cbl-b predisposes to development of type 1 di-
abetes. A, The incidence of type 1 diabetes was measured in wild-type,
Cblb+/2, and Cblb2/2 TCR:insHel mice (n = 25/group). The incidence of
diabetes was statistically higher in both Cblb2/2 and Cblb+/2 TCR insHel
mice compared with Cblb+/+ TCR insHel mice (p , 0.0001; p = 0.0007)
statistical comparison was made by log-rank test. B, Serum anti-HEL IgG
levels were determined by ELISA. Data represent Cblb+/+ TCR insHel (n =
6), Cblb2/2 TCR insHel (n = 13), and Cblb2/2 insHel (n = 6) mice.
Statistical analysis was made by Student t test between Cblb+/+ TCR
insHel and Cblb2/2 TCR insHel mice and showed a significant difference
between the groups ANOVA; p = 0.0318; 2 degrees of freedom.
FIGURE 2. Normal positive and negative selection of HEL-specific T cells
in thymus ofmice lackingCbl-b.A–C, Representative flow cytometric profiles
of thymocytes showing: A, CD4 versus CD8 development and gates used to
differentiate subsets; B and C, expression of HEL-specific 3A9 TCR detected
with 1G12 anti-clonotypic mAb versus CD3 (B) or CD69 (C) on mature CD4
late single-positive (LSP) thymocytes. The numbers indicate the percentage of
thymocytes (A) or CD4 LSP cells (B, C) within the gates shown. D, The ab-
solute number of Hel-specific CD4+1G12+CD692 cells in the thymus of TCR
and TCR:insHelmice on a wild-type and Cbl-b–deficient background. Results
of statistical comparison by Student t test are shown TCR Cblb+/+ versus
Cblb2/2, p = 0.6538; and TCR:insHel Cblb+/+ versus Cblb2/2, p = 0.1484.
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80% of the double-transgenic Cblb2/2 offspring developing di-
abetes (Fig. 1A). Many of the Cbl-b–deficient TCR:insHEL mice
developed anti-HEL IgG autoantibodies in the serum, whereas
none were present in Cbl-b–sufficient controls (Fig. 1B). Cbl-b
deficiency alone was insufficient for spontaneous autoimmunity
in the absence of the elevated T cell frequency conferred by the
TCR transgene, because Cblb2/2 insHEL single-transgenic mice
did not develop anti-HEL IgG autoantibodies (Fig. 1B) or diabetes
(data not shown).
T cell selection in prediabetic mice is normal in the absence of
Cbl-b
To define how Cbl-b deficiency predisposes to diabetes and islet
autoantibodies, we analyzed 8- to 12-wk-old TCR:insHEL animals
that had no evidence of glucosuria. We first asked whether the
mutation had similar effects on thymic tolerance mechanisms to
those previously defined for Aire or Il2 mutations in the same
transgenic model. The fate of HEL-specific CD4+ T cells was
monitored by staining with a 3A9 clonotype TCR-specific mAb,
1G12. In TCR transgenic mice lacking the insHEL gene, positive
selection of 1G12+ thymocytes into the CD4+ T cell lineage oc-
curred equally in the presence or absence of Cbl-b, and there was
no difference in the number of mature CD4+1G12+CD692 T cells
produced in thymus of wild-type or Cblb2/2 TCR mice (Fig. 2 A,
2C). The c-Cbl and Cbl-b proteins regulate cell surface expression
of the TCR–CD3 complex (28) but there was no difference ob-
served in the surface expression of TCR or CD3 on Cblb2/2
thymic T cells compared with wild-type TCR transgenic cells
(Fig. 2B and data not shown).
Negative selection of islet-specific CD4+ T cells in TCR:insHel
mice is under the control of the autoimmune regulator gene Aire
(3, 4). Promiscuous expression of the HEL protein by medullary
thymic epithelial cells causes deletion of the majority of CD4+
T cells during the single-positive stage of development (Fig. 2).
Analysis of negative selection in the thymus of wild-type and
Cblb2/2 TCR:insHel mice by flow cytometry revealed no differ-
ence between the deletion of Hel-specific CD4+1G12+ T cells,
because there were equivalently low numbers of mature CD4+
1G12+CD692 cells in the thymus of both strains, and there was no
change in the levels of CD3 and TCR (Fig. 2B–D). In the periphery,
there was also no difference in the cell surface phenotype or fre-
quency of the residual mature HEL-specific CD4+1G12+ T cells
between wild-type and Cblb2/2 TCR:insHel mice (Fig. 3A, 3B).
We next examined the possibility that diabetes in Cblb2/2 TCR:
insHel mice could reflect absence of thymic or peripheral 1G12+
CD4+CD25+Foxp3+ Tregs, as occurs in TCR insHEL mice lacking
IL-2 (12). Flow cytometric staining nevertheless revealed no dif-
ference in the frequency or absolute number of Tregs in the thy-
mus (data not shown) or the spleen of Cblb+/+ and Cblb2/2 TCR:
insHel mice (Fig. 3C, 3D). Taken together, these results indicate
that Cbl-b has little influence in regulating thymic selection of
islet-specific CD4+ T cells, and furthermore, Cbl-b’s role in reg-
ulating TCR/CD3 levels in thymocytes must be redundant pre-
sumably because of c-Cbl or other ubiquitin ligases.
FIGURE 3. Normal control of peripheral islet-reactive CD4+ T cell
frequency and subsets in mice lacking Cbl-b. A, Representative flow cyto-
metric profiles showing the percentage of Hel-specific CD4+1G12+ cells
in the spleen of TCR and TCR:insHel mice on a wild-type and Cbl-b–
deficient background. B, The number of CD4+1G12+ cells in the spleen of
wild-type and Cblb2/2 TCR (n = 9/group) and TCR:insHel (n = 9/group).
There was no significant difference between Cblb2/2 and Cblb+/+ controls
by Student t test. C, Representative flow cytometric profiles of spleen cells
from mice of the indicated genotypes, gated on CD4+1G12+ and showing
the percentage of gated cells expressing Foxp3. D, The number of spleen
CD4+1G12+ cells expressing Foxp3 in individual mice of the indicated
genotypes. There was no significant difference between Cblb2/2 and
Cblb+/+ controls by Student t test. TCR Cblb+/+ versus Cblb2/2, p =
0.7363; TCR:insHel Cblb+/+ versus Cblb2/2 mice, p = 0.9496.
FIGURE 4. In vivo proliferation of islet-specific peripheral CD4 T cells
is prevented in Cblb deficient mice. A, Representative flow cytometric
profiles of CD4+1G12+ T cells in the pancreatic lymph node of Cblb+/+
and Cblb2/2 TCR:insHel mice. The numbers indicate the frequency of
CD4+ and CD8+ cells within the lymphocyte gate and the frequency of
1G12+ cells within the CD4 compartment. The mean fluorescence intensity
(MFI) of forward light scatter and CD3 show that there is no enlargement
of the islet-reactive CD4 cells and no increase in their surface TCR in Cbl-
b–deficient animals. B, Intracellular flow cytometry staining for the cell
cycle marker Ki67 in gated CD4+1G12+ T cells from Cblb+/+ and Cblb2/2
mice in the pancreatic lymph node. The percentage of Ki67+ cells is
shown. C, Percentage Ki67+ cells among CD4+1G12+ cells in individual
TCR:insHel mice on a Cblb+/+ and Cblb2/2 background. Each symbol re-
presents one mouse. There was no significant difference between Cblb2/2
and Cblb+/+ controls by Student t test. TCR Cblb+/+ versus Cblb2/2, p =
0.6895; TCR:insHel Cblb+/+ versus Cblb2/2, p = 0.6595.
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Defective anergy in islet-specific CD4+ T cells is masked
in vivo in prediabetic mice
Because there was no effect of Cbl-b deficiency on thymic selec-
tion of islet-specific CD4 cells, we next explored the possibility that
the cells that escaped thymic negative selection would fail to be-
come anergic and proliferate in response to the high concentra-
tions of insHEL produced in the pancreatic islets and presented in
the draining pancreatic lymph node (3). Flow cytometric analysis,
nevertheless, revealed no increase in the frequency or cell size of
CD4+1G12+ cells within the draining pancreatic lymph node in
the Cblb2/2 TCR:insHel mice (Fig. 4A). Similar to the thymus,
there was no difference in the levels of TCR and CD3 expression
on the Hel-specific CD4+ T cells in the lymph node of wild-type or
Cblb2/2 TCR:insHel mice (Fig. 4A). Similar to the thymus, there
was no difference in the levels of TCR and CD3 expression on
the Hel-specific CD4+ T cells in the lymph node of wild-type or
Cblb2/2 TCR:insHel mice (Fig. 4A). Moreover, flow cytometric
staining for the nuclear cell Ag Ki67, which marks cells that have
entered cell cycle revealed an equivalent low frequency of ∼10%
Ki67+ cells among CD4+1G12+ T cells of Cblb+/+ and Cblb2/2
TCR:insHel mice (Fig. 4B, 4C). Taken together, these results in-
dicate that the majority of circulating islet-reactive CD4+ T cells
remain tolerant and unresponsive to islet-derived autoantigen de-
spite lacking Cblb.
To explore this further, we set up bone marrow chimeras where
wild-type or Cblb2/2 TCR transgenic bone marrow cells were
transferred to irradiated insHel recipients. Twelve weeks after the
transfer, none of the recipient mice had developed diabetes, and
they were treated with BrdU for 3 d and were analyzed on day
4 for the uptake of BrdU in both CD4+1G12+ and CD4+1G122
cells using flow cytometry (Fig. 5A, 5C). This revealed that ∼75
and 60% of wild-type CD4+1G12+ cells were BrdU+ in the spleen
and pancreatic lymph node, respectively, compared with ∼60
and ∼25% of Cblb2/2CD4+1G12+ T cells that were BrdU+ in the
spleen and pancreatic lymph node, respectively (Fig. 5A, 5C). The
CD4+1G122 cells act as an internal control and displayed just 3–
4% BrdU+ cells in secondary lymphoid tissues consistent with
basal proliferation of naive T cells (Fig. 5A, 5B). These results
indicate that in vivo the majority of circulating islet-reactive CD4+
T cells remain tolerant and unresponsive to islet-derived auto-
antigen in vivo despite lacking Cbl-b. We also examined the
possibility that the loss of cbl-b may disrupt apoptosis that leads
to the inappropriate survival of islet-reactive T cells. To explore
this possibility, we analyzed expression of active caspase 3 by
intracellular FACS staining. Analysis of spleen and lymph node
cells for anti-caspase 3 staining revealed no difference between
wild-type and Cbl-b2/2CD4+ and CD8+ T cells (Fig. 5D). These re-
sults indicate that the Cblb mutation does not affect apoptosis in
the absence of Cblb.
Although there was no evidence of a proliferative response to
islet-derived HELs in vivo, we next asked whether there were
intrinsic differences in the potential to proliferate that could be
revealed by stimulating with different concentrations of HEL Ag in
tissue culture.
Spleen cells from wild-type and Cblb2/2 TCR only or TCR:
insHel mice were stimulated in vitro with HEL Ag, and proli-
FIGURE 5. In vivo proliferation of islet-spe-
cific peripheral CD4 T cells is prevented in Cbl-
b–deficient mice. A, Representative flow cyto-
metric profiles of CD4+1G12+ T cells in the
pancreatic lymph node of Cblb+/+ and Cblb2/2
TCR:insHel mice. The numbers indicate the
frequency of CD4+ and CD8+ cells within the
lymphocyte gate and the frequency of 1G12+
cells within the CD4 compartment. The mean
fluorescence intensity of forward light scatter
and cell surface CD3 show that there is no en-
largement of the islet-reactive CD4 cells and no
increase in their surface TCR in Cbl-b–deficient
animals. B, Intracellular flow cytometry staining
for the BrdU+ in gated CD4+1G12+ T cells from
Cblb+/+ and Cblb2/2 mice in the pancreatic
lymph node. The percentage of BrdU+ cells is
shown. C, Percentage BrdU+ cells among CD4+
1G122 cells in individual TCR:insHel mice on
a Cblb+/+ and Cblb2/2 background. **p = 0.001.
D, Percentage of BrdU+ cells among CD4+
1G12+ cells in individual TCR:insHel mice on
a Cblb+/+ and Cblb2/2 background. Each sym-
bol represents one mouse. There was no signifi-
cant difference between Cblb2/2 and Cblb+/+
controls by Student t test. TCR Cblb+/+ versus
Cblb2/2, p = 0.6895; TCR:insHel Cblb+/+ versus
Cblb2/2, p = 0.6595.
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feration was measured after 72 h. Focusing first on the naive
T cells from TCR-transgenic mice lacking insHEL, we confirmed
previous observations that Cbl-b deficiency lowers the activation
threshold such that the Cblb2/2 T cells proliferated at 5-fold lower
Ag concentrations compared with wild-type T cells (Fig. 6A).
Next, we examined HEL Ag-induced proliferation of T cells from
wild-type and Cblb2/2 TCR:insHel mice by [3H]thymidine in-
corporation or by dilution of the cell membrane dye CFSE fol-
lowing Ag stimulation (Fig. 6B, 6C). By both assays, the HEL-
specific 1G12+CD4+ T cells present in Cblb+/+ TCR:insHel mice
made no T cell-proliferative response to exogenous HEL Ag
in vitro (Fig. 6B, 6C), consistent with their being intrinsically
anergic. By contrast, although a comparable frequency of 1G12+
CD4+ T cells were present in Cblb2/2 TCR:insHel mice, these
showed robust proliferation to exogenous HEL protein in vitro
(Fig. 6B, 6C). Next, we examined the proliferative response on
lymph node cells from wild-type and Cblb2/2 TCR:insHel mice
following depletion of CD4+ Tregs by FACS sorting. The Treg-
depleted lymph node cells were labeled with CFSE and cultured in
the presence of Hel Ag, and proliferation was measured by CFSE
dilution by FACS after 72 h. Wild-type T cells remained un-
responsive to the Hel Ag in vitro following the removal of Tregs.
In contrast, the Cblb2/2 T cells demonstrated a robust and dose-
dependent proliferation to the Hel autoantigen (Fig. 6D). These
results indicate that responsiveness of the Cblb2/2 T cells is in-
dependent of the presence of Tregs. We also examined the effector
response of T cells from wild-type and Cblb2/2 TCR:insHel
mice and spleen cells from wild-type and Cblb2/2 TCR:insHel
mice were activated directly ex vivo with PMA and ionomycin,
and cytokine production was analyzed by intracellular flow
cytometry. Analysis of the CD4+1G12+ cells from both wild-type
and Cblb2/2 cells revealed no difference in the secretion of IFN-
g, IL-4, or IL-17, suggesting that the islet-reactive T cells in the
spleen of Cblb2/2 TCR;insHel mice are not polarized toward any
single Th subset (Supplemental Fig. 1).
Bone marrow chimeras were constructed to examine whether
the defect in T cell anergy was a T cell-intrinsic effect. Bone
marrow from wild-type or Cblb2/2 TCR mice was given to irra-
diated B10.Br insHEL or nontransgenic recipients. Flow cyto-
metric analysis of the thymus and the spleen from nondiabetic
chimeras 12 wk after reconstitution confirmed that in general
there was no defect in positive or negative selection of CD4+
1G12+ T cells in recipients of Cblb2/2 marrow (Fig. 7A). Al-
though there was a statistically significant difference in the
number of CD4+1G12+ cells in the thymus and the spleen of the
mice receiving Cblb2/2 marrow in the insHel+ recipients com-
pared with those that received Cblb+/+ marrow, negative selection
still remained intact with a 10-fold reduction in CD4+1G12+
T cells in the insHel+ versus nontransgenic recipients (Fig. 7A;
p = 0.002 and p = 0.0029, respectively). When the spleen T cells
were assessed for their proliferative responses to exogenous
HEL Ag in vitro, the Cblb2/2 T cells from insHEL+ recipients
FIGURE 6. Cbl-b–deficient islet-reactive CD4
T cells retain capacity to proliferate to HEL in vitro.
A, Proliferation of nontolerant T cells from TCR
transgenic mice lacking insHEL. Incorporation of
[3H]thymidine into spleen cells from Cblb+/+ (n) and
Cblb2/2 (s) TCR tg mice was measured after culture
for 3 d with the indicated concentrations of HEL Ag.
Data show the mean and SD of three mice per group.
B and C, In vitro proliferation of islet-specific T cells
from TCR:insHEL double-transgenic mice. B, Spleen
cells from Cblb+/+ or Cblb2/2 TCR:insHel mice
were labeled with CFSE, cultured for 3 d with the
indicated concentrations of HEL protein, and ana-
lyzed flow cytometrically for CFSE. Histograms
show the percentage of CD4+1G12+7AAD2 cells that
had undergone cell division (i.e., CFSElow) cells. The
data shown are from one of three experiments per-
formed. C, [3H]Thymidine incorporation of spleen
cells from Cblb+/+ (n) and Cblb2/2 TCR:insHel mice
(s) stimulated in vitro with different concentrations
of Hel protein. Data show the response of cells from
individual mice. Statistical analysis by Student t test
showed a significant difference in the response at 1,
3, and 10 mg/ml HEL. p = 0.001; p , 0.0001; p ,
0.0001, respectively. D, Graphs shows the frequency
of divided CD4+1G12+ cells in CD4+ Treg-depleted
spleen cell cultures as measured by CFSE dilution
following in vitro stimulation with different doses of
Hel Ag. The data show results from two representa-
tive experiments for Cblb2/2 (open symbols) and
Cblb+/+ (filled symbols) spleen cell cultures.
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clearly retained responsiveness to Ag, whereas the Cblb+/+ T cells
were completely unresponsive (Fig. 7B; p , 0.0001). These results
confirm that the break in T cell anergy in Cblb2/2 mice is due to
a hematopoietic defect.
Induced Treg differentiation is impaired in Cbl-b–deficient
CD4+ T cells
Recent studies have identified that Cblb mutation decreases Foxp3
induction by TGF-b in activated T cells, reducing the frequency and
function of iTregs (36, 43, 44). To test whether the same defect
occurs in HEL-specific 3A9 T cells, naive spleen CD4+ T cells from
wild-type nontransgenic or Cblb+/+ and Cblb2/2 TCR mice were
cultured in the presence of anti-CD3 and anti-CD28 in the absence
or presence of 0.1 and 0.5 ng/ml TGF-b for 5 d to induce iTreg
differentiation. In the presence of 0.5 ng/ml TGF-b, CD4+ T cells
from wild-type nontransgenic and TCR transgenic mice strongly
induced Foxp3 expression in 63 and 43% of cells, respectively (Fig.
8A). In contrast, the induction of Foxp3 was severely impaired in
Cblb2/2 cells with 8% of cells expressing Foxp3 (Fig. 8A). When
the suppressive activity of the TGF-b–induced iTregs was tested
against CFSE-labeled naive T cell responders in vitro, cells from
both nontransgenic and TCR transgenic Cbl-b wild-type cultures
decreased cell division by the responder cells, whereas Cblb2/2
cultures containing few iTregs were less suppressive (Fig. 8B).
These findings confirm recently published data (36) and raise the
possibility that iTreg formation may also be compromised under
particular conditions in vivo but remain undetected because of
the presence of normal numbers of thymic-derived natural Tregs
(nTregs) in the Cblb2/2 TCR:insHel mice.
Discussion
The findings above extend previous evidence from the KDP rat
strain that Cbl-b is important for regulating islet-specific autoim-
munity (20–22) by showing that Cblb deficiency predisposes
to diabetes and formation of islet autoantibodies in mice (Fig. 1).
In the KDP rat strain, autoimmunity caused by Cblb deficiency
requires additional susceptibility factors, notably a diabetes-
susceptible MHC haplotype. Similarly, we find that autoimmu-
nity is only caused by Cblb deficiency in mice when combined
with a TCR transgene that makes high numbers of islet-reactive
CD4 cells in their thymus. The current study provides a mecha-
nistic insight into how Cbl-b deficiency predisposes to diabetes,
showing that the mutation compromises a different self-tolerance
FIGURE 7. Hematopoietic cell-autonomous effect of Cbl-b deficiency
on islet-reactive CD4+ T cells. A, Bone marrow chimeras were made by
injecting bone marrow from Cblb+/+ or Cblb2/2 3A9 TCR transgenic do-
nors into irradiated B10.BR recipients that either expressed or lacked the
insHEL transgene. A, Number of CD4+1G12+CD692 T cells in thymus and
spleen 12 wk after reconstitution. Data show the mean and SD for each
group of n = 4 mice. Statistical analysis by Student t test showed that there
was no difference in the numbers of CD4+1G12+ cells in the nontransgenic
recipients, but there was a significant difference observed between insHel+
transgenic recipients receiving either Cblb+/+ bone marrow hemopoietic
stem cells compared with Cblb2/2 bone marrow hemopoietic stem cells
p = 0.002 and p = 0.0029 in thymus and spleen, respectively. B, In vitro
proliferation of spleen cells from the mice shown in A stimulated with the
indicated concentrations of Hel protein. Data show the mean and SD of
four mice per group. *p , 0.0001; analysis by Student t test showed
a statistically significant increase in the proliferative response to 3 or 10
mg/ml HEL in cells from insHEL+ recipients of Cblb2/2 marrow com-
pared with insHEL+ recipients of Cblb+/+ marrow. *p , 0.0001; analysis
on nontransgenic recipients showed a significant difference in proliferation
of all HEL Ag concentrations for mice receiving Cblb2/2 marrow com-
pared with Cblb+/+ marrow.
FIGURE 8. Cblb-deficient 3A9 T cells are resistant to TGF-b–induced
iTreg formation. A, Naive CD4+CD62L+CD252 T cells from non-
transgenic or Cblb+/+ and Cblb2/2 TCR transgenic mice were stimulated
with anti-CD3 and anti-CD28 in the presence of the indicated concen-
trations of TGF-b. Development of Foxp3+ iTregs was assessed by flow
cytometry after 5 d. B, CFSE-labeled CD4+CD62L+CD252 naive T cells
from Cblb+/+ TCR mice were used as responder cells in suppression
assays, mixed with irradiated T cell-depleted splenocytes as a source of
APCs and with the cultured CD4 cells shown in A. The cells were mixed in
the two indicated ratios (CFSE-labeled responder cells:APCs:TGF-b–
treated CD4 cells). Anti-CD3 Ab was added to the cultures and CFSE
dilution was assessed by flow cytometry 3 d later.
The Journal of Immunology 7
 o
n









checkpoint from other diabetes susceptibility factors. Unlike di-
abetes susceptibility of NOD mice or Aire-deficient mice (3, 4, 17,
18), Cbl-b deficiency has no effect on the efficiency of thymic
deletion of islet-specific CD4 T cells (Fig. 2). In contrast to mice
lacking IL-2 (12), Cbl-b deficiency has no effect on thymic dif-
ferentiation or peripheral numbers of islet-specific Foxp3+ CD4
cells (Fig. 3), although it does impair TGF-b–induced iTreg for-
mation frommature naive T cells (Fig. 8). Instead, Cbl-b deficiency
causes a selective lesion in the maintenance of proliferative un-
responsiveness among islet-reactive T cells that have escaped
thymic selection, providing direct evidence that T cell anergy oc-
curs in vivo as one of the mechanisms for ensuring organ-specific
self-tolerance. This selective defect in anergy is, nevertheless,
masked in vivo through other Cblb-independent tolerance mecha-
nisms for inhibiting the activation of islet-specific T cells.
The demonstration that Cbl-b is required for clonal anergy in
islet-specific CD4 cells provides direct experimental support for
the view that T cell clonal anergy occurs during physiological
acquisition of self-tolerance. T cell anergy has been extensively
characterized as a state that can be induced in previously activated
T lymphoblasts or cloned T cell lines in tissue culture, where it is
induced by TCR stimulation in the absence of CD28 costimulation
or by pharmacological surrogates, such as prolonged exposure to
ionomycin (37, 39). Under these conditions, Cblb mRNA and
protein are strongly induced, and the cells become unresponsive to
TCR restimulation as measured by proliferation in a manner that
is abolished in Cblb-deficient T cells (37). Ionomycin-anergized T
lymphoblasts retain the ability to form TCR synapses on peptide–
MHC/ICAM1-bearing lipid bilayers but compared with control
T cells these synapses dissolve more rapidly over a period of 35–
60 min in a process that is partly compromised in Cblb-deficient
T cells (37). The role of Cbl-b in T cell clonal anergy has also
been examined in vivo by treating TCR transgenic mice with re-
peated high doses of exogenous Ag (23). This treatment initially
triggers proliferation of initially naive T cells, but after a wave of
apoptosis, the residual cells remaining after 4–10 d have di-
minished capacity to proliferate or make cytokines upon restim-
ulation in vitro or after adoptive transfer and challenge with
exogenous Ag and adjuvant, unless the T cells are Cblb deficient
(23). Similarly, during LCMV virus infection, naive T cells are
initially activated to proliferate and produce cytokines, but during
chronic infection following a high dose of virus, the remaining
T cells become “exhausted” and no longer able to produce cyto-
kines over the course of several weeks unless they are Cblb de-
ficient (32). Collectively, these studies firmly establish a role for
Cbl-b in the desensitization of previously activated T cells during
the response to exogenous Ag but provide no information about
the role of Cbl-b or T cell anergy in self-tolerance.
One of the two initial studies of Cblb-deficient mice concluded
this mutation was sufficient on its own to cause a systemic auto-
antibody syndrome (29), but it is likely those findings were con-
founded by the mixed 129/Sv 3 B6 strain background of these
animals, which is sufficient on its own to cause the observed
syndrome of systemic autoantibodies (45). We do not detect any
significant increase in formation of antinuclear autoantibodies or
lymphadenopathy in mice with the same Cblb-targeted mutation
(29) backcrossed to the C57BL/6 background (data not shown),
nor is there any spontaneous Ab formation to islet HELs despite
the H2k background being a high responder strain to HEL Ag (Fig.
1). In our studies, although Cbl-b deficiency caused a defect in
islet-specific T cell anergy that could be measured upon stimu-
lation with exogenous Ag in vitro, this defect is not manifest by
the majority of islet-specific T cells in vivo because the Cblb-
deficient T cells bearing the HEL-reactive TCRs were not en-
larged nor was there an increased percentage in cell cycle (Fig. 4).
Also the Cblb-deficient islet-reactive CD4+ T cells are not po-
larized toward any Th subset but can secrete Th1, Th1, and Th17
cytokines.
A number of Cblb-independent tolerance processes could ac-
count for the maintenance of self-tolerance in the islet-reactive
T cells in vivo. First, other ubiquitin ligases that are induced in
islet-reactive CD4 cells could partially desensitize TCR signaling
and synapse formation, as has been observed during ionomycin
treatment of Cblb-deficient T cells (37). This residual anergy may
prevent proliferation in response to the concentrations of HEL
peptide presented in the pancreatic lymph node but be over-
whelmed when higher concentrations of exogenous HEL peptide
are presented in vitro. Second, Cblb-independent processes of
anergy restraining islet-reactive T cells in vivo may be overcome
in vitro because Ag is presented by activated dendritic cells in
culture. Third, there may be active suppressive mechanisms at
work in the pancreatic lymph node that do not function as effi-
ciently in dispersed cultures of lymphocytes, such as Foxp3+ Tregs
or local secretion of TGF-b. Given the poor differentiation of
iTregs from activated Cblb2/2 TCR CD4 cells, but normal fre-
quencies of Foxp3+CD4+ nTregs in vivo, the intrinsic defect in
clonal anergy may be masked by the action of nTregs in vivo.
The findings in this study highlight that mutations in Cbl-b that
compromise T cell anergy to islet-derived Ag are insufficient to
trigger organ-specific autoimmune disease because of the presence
of other self-tolerance checkpoints that prevent autoimmunity (46).
The effects of Cblb deficiency are only manifest as autoimmunity
when peripheral tolerance is stressed by increasing the frequency
of autoreactive T cells through elevated thymic production in the
TCR insHEL transgenic mice studied in this study. Similarly, the
autoimmune effects of Cblb mutation in rats are only manifest as
insulitis, diabetes, and thyroiditis when combined with a diabetes-
susceptible MHC haplotype (20–22) that, speculatively, may di-
minish thymic negative selection of islet-specific CD4 cells (47).
Even with these combined defects, diabetes only develops after
a variable latent phase. Rare islet-specific T cells may be activated
to overcome other tolerance mechanisms in Cblb2/2 TCR insHEL
in a manner analogous to that observed in this study in vitro, for
example, triggered by intermittent increases in Ag release from
pancreatic islets or transient activation of dendritic cells that could
combine with a decreased functional capacity of iTregs. Thus,
collectively, these factors could act to precipitate spontaneous
organ specific autoimmunity.
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